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treatment. Furthermore, adropin34 –76 suppressed cAMP activated protein kinase A (PKA) activities, resulting in reduced
phosphorylation of inositol trisphosphate receptor, which
mediates endoplasmic reticulum calcium efflux, and of cAMPresponsive element– binding protein, a key transcription factor
in hepatic regulation of glucose metabolism. Adropin34 –76
directly affected liver metabolism, decreasing glucose production and reducing PKA-mediated phosphorylation in primary
mouse hepatocytes in vitro. Our findings indicate that major
hepatic signaling pathways contribute to the improved glycemic
control achieved with adropin34 –76 treatment in situations of
obesity.

Adropin is a small peptide that is implicated in the physiological regulation of metabolic homeostasis (1–3). In mice and
humans, adropin is abundantly expressed in the brain as well as
the liver (3). Although the source and the mechanism of secretion are elusive, circulating adropin is readily detected in both
mice and humans (2–5).
Mounting evidence indicates that adropin may act as a hormone in regulating metabolic homeostasis, in part by controlling substrate (glucose and fatty acid) metabolism in skeletal
muscle (1–3). Using male C57BL/6J (B6)8 mice, our previous
studies identified a therapeutic potential for adropin in treating
impaired glycemic control that is frequently observed with obesity (1, 3). Adropin knockout (AdrKO) mice are insulin-resistant, whereas transgenic overexpression of adropin improves
glycemic control of the mice maintained on either chow or
8

The abbreviations used are: B6, C57BL/6J; PKA, protein kinase A; IP3R, inositol-1,4,5-triphosphate receptor; JNK, c-Jun N-terminal kinase; G6Pase, glucose-6-phosphatase; PEPCK, phosphoenolpyruvate carboxykinase; ER,
endoplasmic reticulum; AdrKO, adropin knockout; HFD, high fat diet; DIO,
diet-induced obese; GPCR, G protein– coupled receptor; IRS, insulin receptor substrate; GSK, glycogen synthase kinase; PC, pyruvate carboxylase;
PERK, PKR-like ER kinase; IRE, inositol-requiring enzyme; ATF, activating
transcription factor; eIF, eukaryotic initiation factor; BiP, binding immunoglobulin protein; IKK, inhibitor B kinase; TAG, triacylglycerol; SREBP, sterol
regulatory element– binding protein; CREB, cAMP-responsive elementbinding protein; GK, glucokinase; CRTC, CREB-regulated transcription coactivator; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; XBP1s,
spliced form of X-box– binding protein 1.
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The peptide hormone adropin regulates energy metabolism
in skeletal muscle and plays important roles in the regulation of
metabolic homeostasis. Besides muscle, the liver has an essential role in regulating glucose homeostasis. Previous studies
have reported that treatment of diet-induced obese (DIO) male
mice with adropin34 –76 (the putative secreted domain) reduces
fasting blood glucose independently of body weight changes,
suggesting that adropin suppresses glucose production in the
liver. Here, we explored the molecular mechanisms underlying
adropin’s effects on hepatic glucose metabolism in DIO mice.
Male DIO B6 mice maintained on a high-fat diet received five
intraperitoneal injections of adropin34 –76 (450 nmol/kg/injection) over a 48-h period. We found that adropin34 –76 enhances
major intracellular signaling activities in the liver that are
involved in insulin-mediated regulation of glucose homeostasis.
Moreover, treatment with adropin34 –76 alleviated endoplasmic
reticulum stress responses and reduced activity of c-Jun N-terminal kinase in the liver, explaining the enhanced activities of
hepatic insulin signaling pathways observed with adropin34 –76

Adropin improves liver glucose metabolism in obesity

Results
Adropin34 –76 treatment enhances intracellular signaling
actions underlying insulin’s effect on hepatic glucose
metabolism
In the current report, we employ an adropin34 –76 treatment
protocol (five injections over 48 h with 450 nmol/kg for each
injection) previously assessed in a dose-response study investigating effects on glucose homeostasis (3). The specific dosage
and time period of treatment robustly enhance glucose tolerance as well as whole-body insulin sensitivity without altering

body weight in the DIO mice (3, 6). In the current studies, we
first confirmed adropin’s glucose-lowering effect by showing
that adropin34 –76 treatment reduced fasting hyperglycemia as
compared with the vehicle treatment in the DIO mice (Fig. S1).
Insulin plays an essential role in controlling hepatic glucose
production in part by modulating liver metabolism (7–9). We
then assessed hepatic intracellular signaling pathways that are
employed by insulin to regulate glucose metabolism. Analysis
of key mediators of insulin signaling showed marked differences between adropin34 –76 treatment and vehicle control
groups (Figs. 1 and 2). Increased Ser307 phosphorylation of
insulin receptor substrate 1 (IRS1) that is frequently observed in
B6 mice fed HFD (Fig. S2A) (7, 16) was markedly reduced by
adropin34 –76 treatment (Fig. 1A). Ser307 phosphorylation
inhibits IRS1 signaling by antagonizing its tyrosine phosphorylation by insulin receptor (7, 16). Here we showed that the phosphorylation of IRS1 on Tyr608 that was reduced in mice on HFD
(Fig. S2A) was increased with adropin34 –76 treatment (Fig. 1A).
Hepatic expression of IRS2 was reduced in mice fed HFD (Fig.
S2A) (7, 16), but this level in DIO mice was increased with
adropin34 –76 treatment (Fig. 1B).
AKT is a critical mediator of IRS1/2 signaling (7), and Ser473
phosphorylation is frequently used as a surrogate marker of
AKT activity (6). In our studies, we showed that AKT Ser473
phosphorylation was increased with adropin34 –76 treatment
(Fig. 2A), indicating an activation of AKT (6). Activated AKT
phosphorylates glycogen synthase kinase-3 (GSK-3) and members of the Forkhead box O (FoxO) family (7). We found that
adropin34 –76 treatment increased the phosphorylation level of
Ser9 in GSK-3␤ (Fig. 2B), indicating an inhibition of GSK activity (7). The inhibition of GSK activity is expected to promote
glycogen synthesis (7), and consistent with this prediction, liver
glycogen content was increased following adropin34 –76 treatment (Fig. 2C). FoxO1 phosphorylation by AKT results in its
nuclear exclusion and degradation, leading to inhibition of
FoxO1-dependent transcription (7). Here we found that
adropin34 –76 treatment reduced the nuclear level of FoxO1 as
well as its whole-tissue level (Fig. 2D), which is expected to lead
to an inhibition of FoxO1 transcription activity.
FoxO1 down-regulates the expression of glucokinase (Gck), a
key enzyme facilitating glucose uptake, and up-regulates the
expressions of G6Pase (G6pc) and phosphoenolpyruvate carboxykinase (PEPCK) (Pck1), enzymes involved in hepatic glucose production (17). Consistent with these effects, we found
that adropin34 –76 treatment increased Gck expression (Fig. 3A),
whereas it down-regulated the expressions of G6pc and Pck1
(Fig. 3B). Pyruvate carboxylase (PC) is another enzyme playing
a key role in hepatic gluconeogenesis (8, 18). However,
adropin34 –76 treatment altered neither its expression level
(percentage of vehicle: adropin, 101 ⫾ 5.5%; vehicle, 100 ⫾
1.7%) nor the level of acetyl-CoA (Fig. S3A), an allosteric
regulator of PC activity (8, 18). The gene expression level of
liver pyruvate kinase (Pklr), the last rate-limiting enzyme in
the hepatic glycolysis pathway, was also not altered with
adropin34 –76 treatment (Fig. 3A).
Taken together, our data suggest that adropin34 –76 treatment rapidly enhances intracellular signaling actions that are
employed by insulin. It should be noted that the DIO mice
J. Biol. Chem. (2019) 294(36) 13366 –13377
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high-fat diet (HFD) (1, 3). Moreover, treatment of diet-induced
obese (DIO) B6 mice with the putative secreted domain of adropin, adropin34 –76, improves glucose tolerance as well as wholebody insulin sensitivity (3, 6). These responses are accounted
for at least in part by adropin’s enhancement of the insulin
intracellular signaling pathway in skeletal muscle (6).
Adropin is expressed in the liver (3) and appears to be co-regulated with genes involved in hepatic glucose and lipid metabolism (5). The liver is an important target organ for insulin, and
insulin’s metabolic actions in the liver are essential for glucose
homeostasis (7, 8). Our previous studies demonstrate that
AdrKO mice display an impaired suppression of hepatic glucose production under a hyperinsulinemic-euglycemic clamp
condition, indicating that adropin deficiency associates with
insulin resistance in the liver (1). In addition, fasting hyperinsulinemia and hyperglycemia are observed in AdrKO mice (1).
As liver glucose production is a major determinant of fasting
blood glucose level and the suppression of liver glucose production has a central role in insulin’s glucose-lowering effect (9),
these observations suggest that adropin influences insulin
action and glucose metabolism in the liver (1, 10). Moreover, we
have reported that adropin34 –76 treatment reduced fasting
hyperglycemia and hyperinsulinemia in diabetic DIO mice (3),
indicating that adropin treatment improves hepatic glucose
metabolism and may enhance insulin’s hepatic intracellular signaling actions in obesity.
In obesity, insulin resistance and the aberrant hepatic glucose
metabolism involve multiple mechanisms (7, 8). Among them,
obesity-associated endoplasmic reticulum (ER) stress leads to cellular insulin resistance in part by activating c-Jun N-terminal
kinase (JNK), the activation of which plays a prominent role in
impairing the insulin intracellular signaling pathway (11, 12).
Insulin signaling interacts with cAMP-dependent pathways
to coordinately regulate glucose metabolism in the liver (13).
cAMP is a second messenger in the G protein– coupled receptor (GPCR) signaling pathway, and cAMP-dependent pathways
play a central role in mediating the hepatic actions of glucagon,
another key hormone in controlling glucose homeostasis (13).
Of relevance, recent studies suggest that GPCR mediates adropin’s intracellular signaling pathways (14, 15).
Here we report studies that address the effects of
adropin34 –76 treatment on key signaling pathways underlying
insulin’s effect on hepatic glucose metabolism in DIO mice. We
further investigated adropin’s actions on ER stress and JNK
activity. In addition, we explored the effect of adropin on
cAMP-dependent signaling pathways in the liver.

Adropin improves liver glucose metabolism in obesity

displayed no significant difference in circulating insulin levels
between the adropin-treated and vehicle-treated group (2.27 ⫾
0.20 versus 2.38 ⫾ 0.14 ng/ml), which is consistent with the
previous report (3). Therefore, the observed effects of insulinsignaling action are not accounted for by changes in circulating
insulin concentrations.
Adropin34 –76 treatment alleviates hepatic ER stress responses
ER stress triggers unfolded protein responses through pathways mediated by three classical signal transducers: PKR-like
ER kinase (PERK), inositol-requiring enzyme 1␣ (IRE1␣), and
activating transcription factor 6 (ATF6) (11, 19). PERK activation results in phosphorylation level of eukaryotic initiation factor 2␣ (eIF2␣) (19). In our studies, we found that adropin34 –76
treatment of DIO mice decreased phosphorylation of eIF2␣
(Fig. 4A) that was increased by high fat diet feeding (Fig. S2B).
The result shows that adropin treatment may attenuate PERK
activation. Activation of IRE1␣ leads to increases in the spliced
form of X-box– binding protein 1 (XBP1s) and nuclear translocation of XBP1s protein (19). Our data showed that
adropin34 –76 treatment reduced the nuclear level as well as the
whole-tissue level of XBP1s protein (Fig. 4B), thus suggesting
an inhibition of adropin on the signaling actions of IRE1␣
branch. Activation of ATF6 in response to ER stress induces
proteolytic cleavage and nuclear translocation of the cleaved

13368 J. Biol. Chem. (2019) 294(36) 13366 –13377

form (19); however, we did not detect changes in the nuclear
level of ATF6 (the cleaved form) with adropin34 –76 treatment
(percentage of vehicle: adropin, 96 ⫾ 9.2%; vehicle, 100 ⫾ 18%).
The activation of unfolded protein response signaling pathways up-regulates the expression of molecular chaperones
facilitating protein folding, including binding immunoglobulin
protein (BiP), to counter ER stress (20). We observed a decrease
in BiP message level following adropin treatment, which is in
line with the attenuated ER stress resulting in a reduced
demand of molecular chaperones. However, the level of BiP
protein was not altered by adropin (Fig. 4C), which might be
accounted for by the long half-life of the protein (21).
Adropin34 –76 treatment diminishes JNK signaling in the liver
ER stress can lead to the activations of JNK signaling as well
as inhibitor B kinase (IKK) (7, 19, 22, 23). Consistent with the
previous finding (22), in parallel with inducing ER stress in liver,
high fat diet feeding led to increases in the phosphorylation
levels of JNK and c-Jun (the canonical JNK substrate) (Fig. S2B),
which together indicates JNK activation (22). These phosphorylation levels were reduced following adropin34 –76 treatment
(Fig. 4, D and E), which indicates a suppression of JNK activity
by adropin. JNK regulates expression of pro-inflammatory
cytokines that can antagonize insulin receptor signaling (23).
However, the expression levels of three key cytokines, including

Downloaded from http://www.jbc.org/ at Washington University on November 21, 2019

Figure 1. Adropin34 –76 treatment enhanced IRS signaling in the liver. A, the phosphorylation levels of Ser307 in IRS1 (n ⫽ 3–5) and total IRS1 protein levels
(n ⫽ 4 –5) as well as the phosphorylation levels of Tyr608 in IRS1 immunoprecipitates (IP) (n ⫽ 4) were measured by Western blotting (IB). The Western blotting
of the phosphorylation levels of Ser307 in IRS1 were repeated (n ⫽ 4 –5), and similar changes were detected. ␣-Tubulin was used as the loading control for pIRS1
(Ser307) and total IRS1. The same ␣-tubulin band serving as the loading control for total IRS1 was used as the loading control for the blots of pAKT (Ser473) and
total AKT (Fig. 2A) and the blots of pIKK (␣/␤) (Ser176/180) and total IKK (␣/␤) (Fig. S6). B, IRS2 protein levels (n ⫽ 4 –5) and message levels (Irs2) (n ⫽ 5– 6) were
determined by Western blotting and RT-PCR, respectively. In Western blotting, GAPDH was used as the loading control for IRS2. The same GAPDH band was
used as the loading control for the blots of p-c-Jun (Ser63) and total c-Jun (Fig. 4E) and the blots of pCREB (Ser133) and total CREB (Fig. 8B). *, p ⱕ 0.05; ***, p ⬍
0.0005, adropin versus vehicle. Error bars, S.E.

Adropin improves liver glucose metabolism in obesity

Figure 2. Adropin34 –76 treatment enhanced AKT signaling in the liver. A
and B, the phosphorylation levels of Ser473 in AKT and total AKT protein levels
(n ⫽ 4) (A) and the phosphorylation levels of Ser9 in GSK 3␤ and total GSK 3␤
protein levels (n ⫽ 4 –5) (B) were determined by Western blotting. In A, ␣-tubulin was used as the loading control. The same ␣-tubulin band was used as
the loading control for the blot of total IRS1 (Fig. 1A) and the blots of pIKK
(␣/␤) (Ser176/180) and total IKK (␣/␤) (Fig. S6). In B, GAPDH was used as the
loading control. C, glycogen levels were determined and were normalized to
tissue masses (n ⫽ 8). D, nuclear levels (n ⫽ 4 –5) and whole-tissue level (n ⫽
4) of FoxO1 were measured by Western blotting. Histone H3 was used as the
loading control in the blot of nuclear lysates. The same histone H3 band
was used as the loading control for the blots of (n)SREBP1c (Fig. 6A),
(n)CRTC2 (Fig. 8B), and (n)NF-B p65 (Fig. S6). GAPDH was used as the
loading control in the blot of whole-tissue lysates. *, p ⱕ 0.05, adropin
versus vehicle. Error bars, S.E.

tumor necrosis factor (Tnf), interleukin-1b (Il1b), and interleukin-6 (Il6), were not changed with adropin34 –76 treatment (Fig.
S4). Inhibition of JNK may promote expression of fibroblast
growth factor-21 (FGF21), which could contribute to an improved
insulin action (23), whereas in our studies, adropin34 –76 treatment
did not affect Fgf21 expression (Fig. S5). In addition, we found that
adropin treatment did not alter either the phosphorylation levels
of IKK or the nuclear level of NF-B that translocates into the
nucleus upon IKK activation (Fig. S6). Taken together, the results
demonstrate that adropin exerts a selective effect on liver JNK in
the DIO mice.
Adropin34 –76 treatment down-regulates hepatic lipogenic
genes
Our previous studies demonstrated that 14 days of
adropin34 –76 treatment reduced hepatic steatosis in DIO mice,
and transgenic overexpression of adropin markedly reduced
plasma triacylglycerol (TAG) level (3). Our current studies
showed that short-term treatment of adropin resulted in a
trend for the reduction of hepatic TAG content (Fig. 5A), which

confirms the previous finding employing the same treatment
protocol (3). This short-term treatment did not alter plasma
TAG levels (adropin, 59 ⫾ 15 mg/dl; vehicle, 71 ⫾ 7.8
mg/dl).The shorter time period (2 days) of treatment in the
current studies may underlie the lack of significant changes in
the TAG levels. Despite this, we observed that adropin34 –76
treatment significantly reduced or induced strong trends of
decrease in the expression of the enzymes involved in de novo
fatty acid synthesis (Fig. 5B) and TAG synthesis (Fig. 5C). The
expression of acetyl-CoA carboxylase-␤ that plays a key role in
fatty acid oxidation (24, 25) was reduced by adropin (Fig. 5D).
The adropin-induced down-regulation of acetyl-CoA carboxylase expression is consistent with our previous finding that
adropin34 –76 treatment reduced the level of hepatic malonylCoA, the product of acetyl-CoA carboxylase and a negative regulator of fatty acid oxidation (6).
The expression of lipogenic enzymes is partly controlled by sterol regulatory element–binding protein 1c (SREBP1c) located in
the ER membrane. Post-translational processing of nascent (precursor) SREBP1c results in the release of the short-form SREBP1C
that translocates into the nucleus to regulate gene transcription
(24). Here, we observed that adropin34 –76 treatment reduced
nuclear (short form) SREBP1c levels without altering the levels of
its precursor (Fig. 6A), which indicates that adropin suppresses
post-translational processing of SREBP1c.
Under normal conditions, BiP interacts with precursor
SREBP1c to sequester it at the ER membrane (26). However, ER
stress disrupts this interaction and thus promotes the posttranslational processing and nuclear translocation of SREBP1c
(26). We observed that adropin34 –76 treatment increased the
level of BiP in the SREBP1c immunoprecipitates from microsomal fraction (Fig. 6B), as indicated by the elevated ratio of BiP
to SREBP1c. The result suggests that adropin promotes the
J. Biol. Chem. (2019) 294(36) 13366 –13377
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Figure 3. Adropin34 –76 treatment altered the expression of glucose metabolic genes in the liver. The message levels of genes in glycolysis (A),
including glucokinase (Gck) (n ⫽ 6) and liver pyruvate kinase (Pklr) (n ⫽ 6), and
genes in glucose production (B), including G6Pase (G6pc) (n ⫽ 6) and PEPCK-1
(Pck1) (n ⫽ 6 –7) were determined by real-time RT-PCR. *, p ⱕ 0.05, adropin
versus vehicle. Error bars, S.E.

Adropin improves liver glucose metabolism in obesity

interaction between BiP and SREBP1c, which would contribute
to the reduction of precursor SREBP1c processing and subsequent nuclear translocation of the short form.
Lipid intermediates impact cellular insulin signaling actions
(8), and we performed lipidomic profiling to determine the levels of several lipid species that are known to modulate insulin
pathways. Adropin34 –76 treatment did not alter the levels of
major long-chain acyl-CoAs, although reduced stearoyl-CoA
(18:0) was observed (Fig. S3B), which might be accounted for by
the reduced expression of elongase (Elovl6) (Fig. 5B). Further
analysis of the ratio of saturated acyl-CoA (the sum of 16:0 and

13370 J. Biol. Chem. (2019) 294(36) 13366 –13377

18:0) to unsaturated acyl-CoA (the sum of 16:1 and 18:1) reveals
a trend of decrease in adropin-treated mice compared with
vehicle-treated ones (Fig. S3C). Adropin34 –76 treatment also
did not alter the levels of either ceramide (Fig. S3D) or diacylglycerol (adropin/vehicle ratio: 1,2-dipalmitoylglycerol, 0.8; 1,3dipalmitoylglycerol, 1.0). Moreover, the treatment did not
affect the phosphorylation level of Thr172 in AMP-activated
protein kinase (Fig. S7), an enzyme involved in nontranscriptional regulation of lipid metabolism (27), which indicates that
adropin does not alter AMP-activated protein kinase activity in
the DIO liver.

Downloaded from http://www.jbc.org/ at Washington University on November 21, 2019

Figure 4. Adropin34 –76 treatment alleviated ER stress responses and diminished JNK signaling in the liver. A and B, the phosphorylation levels of Ser51
in eIF2␣ and total eIF2␣ levels in whole-tissue lysates (A) and the levels of XBP-1s in nuclear lysates (n ⫽ 4 –5) and whole-tissue lysates (n ⫽ 4) (B) were
determined by Western blotting (n ⫽ 4 –5). In A, ␣-tubulin was used as the loading control. In B, histone H3 was used as the loading control for nuclear XBP1s,
and GAPDH was used as the loading control for whole-tissue XBP1s. C, BiP message (Hspa5) levels (n ⫽ 6) and protein levels in whole-tissue lysates (n ⫽ 4 –5)
were determined by real-time RT-PCR and Western blotting, respectively. In Western blotting, GAPDH was used as the loading control for BiP. D and E, the
phosphorylation levels of Thr183/Tyr185 in JNK and total JNK levels (n ⫽ 4 –5) (arrows indicating JNK splice isoforms) (D) and the phosphorylation levels of Ser63
in c-Jun and total c-Jun levels (n ⫽ 4 –5) in whole-tissue lysates (E) were determined by Western blotting (n ⫽ 4 –5). In D, ␣-tubulin was used as the loading
control. The same ␣-tubulin band was used as the loading control for the blot of whole-tissue IP3R1 (Fig. 7). In E, GAPDH was used as the loading control. The
same GAPDH band was used as the loading control for the blot of total IRS2 (Fig. 1B) and the blots of pCREB (Ser133) and total CREB (Fig. 8B). *, p ⱕ 0.05; ****,
p ⬍ 0.0001, adropin versus vehicle. Error bars, S.E.

Adropin improves liver glucose metabolism in obesity

Figure 6. Adropin34 –76 treatment reduced the nuclear level of SREBP1c in the liver. A, the nuclear levels of SREBP1c (n ⫽ 4 –5) and the levels of precursor
SREBP1c in whole-tissue lysates (n ⫽ 4 –5) were measured by Western blotting. GAPDH and histone H3 were used as the loading control in the blot of
whole-tissue lysates and nuclear lysates, respectively. The same histone H3 band was used as the loading control for the blots of (n)FoxO1 (Fig. 2D), (n)CRTC2
(Fig. 8B), and (n)NF-B p65 (Fig. S6). B, BiP protein levels in the immunoprecipitates (IP) of precursor SREBP1c from microsomal fractions were determined by
Western blotting (IB) (n ⫽ 4 –5). The blotting was repeated twice, and the blot with 3 samples/treatment was presented. *, p ⱕ 0.05; **, p ⬍ 0.01, adropin versus
vehicle. Error bars, S.E.

Adropin34 –76 treatment coordinately alters the
phosphorylation levels of inositol-1,4,5-triphosphate
receptor (IP3R) in the liver
Disruption of ER calcium homeostasis leads to ER stress, and
the impairment of ER calcium retention underpins the development of hepatic ER stress in obesity (28). IP3R is the major
channel mediating calcium efflux from ER, and its phosphorylation state that impacts channel activity is modulated by
kinases such as PKA and AKT (29, 30). In our studies, obese

mice (on a high fat diet) displayed an increased phosphorylation
level of PKA substrate sites in IP3R as compared with the mice
on a low fat diet (Fig. S8), which indicates a potential activation
of the channel in mediating calcium efflux from ER (30).
Adropin34 –76 treatment of the obese mice reduced this level,
suggesting the attenuation of the activation in the DIO mice
(Fig. 7).
In parallel to the enhanced AKT action, adropin34 –76 treatment increased the phosphorylation level of the AKT substrate
J. Biol. Chem. (2019) 294(36) 13366 –13377
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Figure 5. Adropin34 –76 treatment reduced the expressions of lipogenic genes in the liver. A, triacylglycerol contents were measured and were normalized
to tissue masses (n ⫽ 8). Real-time RT-PCR was performed to determine the message levels of genes in de novo fatty acid synthesis, including acetyl-CoA
carboxylase-␣ (Acaca) (n ⫽ 6), fatty acid synthase (Fasn) (n ⫽ 5– 6), stearoyl-CoA desaturase (Scd1) (n ⫽ 6), and Elovl6 (elongase) (n ⫽ 6) (B); de novo TAG
synthesis, including mitochondrial glycerol-3-phosphate acyltransferase (Gpam) (n ⫽ 6) and diacylglycerol acyltransferase-2 (Dgat2) (n ⫽ 6) (C); and acetyl-CoA
carboxylase-␤ (Acacb) (n ⫽ 5) (D). *, p ⱕ 0.05, adropin versus vehicle Error bars, S.E.

Adropin improves liver glucose metabolism in obesity
sistent with the observed reduction of PKA-mediated IP3R phosphorylation following adropin treatment (Fig. 7). Besides IP3R, the
cAMP-responsive element-binding protein (CREB) is a well-established PKA substrate and a central transcription factor mediating cAMP-dependent gene transcription (31). Here, we demonstrate that adropin34 –76 treatment reduced the phosphorylation
level of Ser133 in CREB (Fig. 8B), indicating a potential reduction of
CREB transcriptional activity (31). Moreover, adropin treatment
reduced the nuclear level of CREB-regulated transcription co-activator 2 (CRTC2) (Fig. 8B), a key co-activator of CREB in cAMPdependent gene transcription (32). Together, these results suggest
that adropin actions suppress the cAMP-PKA signaling pathway
in the liver of DIO mice.
Adropin34 –76 directly suppresses glucose production in
cultured hepatocytes

Figure 7. Adropin34 –76 treatment decreased PKA phosphorylation and
increased AKT phosphorylation of IP3R in the liver. A, the phosphorylation
levels of PKA substrate sites (n ⫽ 4) and the phosphorylation levels of AKT
substrate sites in IP3R1 following immunoprecipitation (IP) of IP3R1 as well as
total IP3R1 levels in whole-tissue lysates (n ⫽ 4 –5) were determined by Western blotting (IB). ␣-Tubulin was used as the loading control for whole-tissue
IP3R1. The same ␣-tubulin band was used as the loading control for the blots
of pJNK (Thr183/Tyr185) and total JNK (Fig. 4D). **, p ⬍ 0.01, adropin versus
vehicle. Error bars, S.E.

site in IP3R (Fig. 7), indicating an inhibition of the channel
activity (30). The concerted effects by adropin on IP3R phosphorylation state are expected to lead to a suppression of IP3R
channel activity resulting in a reduced calcium efflux from ER.
Adropin34 –76 treatment inhibits PKA signaling actions in the
liver
In addition to AKT, PKA plays a key role in regulating liver
glucose metabolism (13). Here, we demonstrate that adropin34 –76
treatment decreased PKA activity in liver crude cytosolic extracts
(percentage of vehicle: adropin, 74 ⫾ 8.4%; vehicle, 100 ⫾ 3.6%;
p ⫽ 0.05) as well as reduced the level of cAMP (Fig. 8A), the canonical second messenger activating PKA (31). These changes are con-
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Discussion
The major finding of this report is that adropin34 –76 treatment enhances hepatic IRS-AKT signaling actions in DIO mice.
These data suggest that adropin sensitizes the insulin intracellular signaling pathway, leading to reduced fasting hyperglycemia. The finding is in line with our previous study showing that
adropin34 –76 treatment sensitizes insulin intracellular signaling
pathways in skeletal muscle in DIO mice (6) as well as the report
demonstrating that adropin augments AKT signaling actions
in endothelial cells (34). Furthermore, consistent with our current results, recent data reveal that adropin34 –76 treatment
enhances IRS and AKT signaling actions in the heart (35). In the
current studies, despite the enhanced intracellular signaling
actions, the serum insulin level was not altered following adropin treatment. We believe the lack of changes is likely due to the
short time period of the treatment because our previous studies
demonstrate a marked reduction of serum insulin in the mice
with transgenic overexpression of adropin (3).
Through enhancing AKT signaling, adropin suppresses the
action of FoxO1, which can up-regulate the transcription of
Gck, the enzyme catalyzing glucose influx (9, 17). Along with

Downloaded from http://www.jbc.org/ at Washington University on November 21, 2019

Primary cultured mouse hepatocytes were used to explore
whether adropin34 –76 would exert a direct effect on liver glucose production. Endogenous glucose production was induced
in serum-starved primary cultured hepatocytes following
the addition of glucagon and pyruvate (33). We found that
adropin34 –76 treatment attenuated glucose production (Fig.
9A), which demonstrates that adropin directly inhibits glucose
production in hepatocytes. To explore the underlying mechanisms, we assessed cAMP-PKA signaling. In our experimental
settings, we found that the cAMP level in primary hepatocytes
was too low, which would prevent a potential decrease in
response to adropin34 –76 from being detected. We then measured cAMP level in HepG2 liver cells treated with the same
amount of adropin34 –76 as in primary hepatocytes and found
decreases in this level, as compared with vehicle-treated cells
(Fig. 9B). Consistent with the in vivo findings, adropin34 –76
reduced the phosphorylation levels of CREB and multiple other
PKA substrates in the primary hepatocytes (Fig. 9C). Expression levels of G6pc and Pck1 in the primary hepatocytes were
also suppressed by adropin34 –76 treatment (Fig. 9D).
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Figure 8. Adropin34 –76 treatment decreased cAMP level and the phosphorylation level of CREB in the liver. A, cAMP contents were measured and were
normalized to tissue masses (n ⫽ 8). B, the phosphorylation levels of Ser133 in CREB and total CREB levels in whole-tissue lysates (n ⫽ 4 –5) as well as the nuclear
levels of CRTC2 (n ⫽ 4 –5) were measured by Western blotting. GAPDH and histone H3 were used as the loading control in whole-tissue lysates and nuclear
lysates, respectively. The same GAPDH band was used as the loading control for the blot of total IRS2 (Fig. 1B) and the blots of p-c-Jun (Ser63) and total c-Jun (Fig.
4E). The same histone H3 band was used as the loading control for the blots of (n)FoxO1 (Fig. 2D), (n)SREBP1c (Fig. 6A), and (n)NF-B p65 (Fig. S6). *, p ⱕ 0.05,
adropin versus vehicle. Error bars, S.E.

this, adropin suppresses GSK3 (7), the activation of which
inhibits glycogen synthesis. These changes are expected to promote glycogen synthesis and lead to the observed increase in
glycogen content. Moreover, the suppression of FoxO1 action
would also contribute to the down-regulation of Pck1 and G6pc,
two key enzymes involved in hepatic glucose production (9, 17).
Together, the concerted changes in the molecular machinery
mediating glucose flux would ultimately result in the net reduction of hepatic glucose output, which underlies adropin’s effect
on fasting blood glucose level. In support of our findings, overexpression of GK in the liver of Zucker diabetic fatty rats has
been shown to correct hepatic glucose flux and normalize
plasma glucose level (36). Moreover, liver-specific ablation of
FoxO, which reduces the G6Pase/GK ratio, increased glucose
uptake and utilization and consequently suppressed hepatic
glucose production (17). Of interest, our studies provide further
support for GK as a target of novel anti-hyperglycemic drugs
(36). One concern with targeting GK is that its activation

may promote de novo lipogenesis (17), thus leading to hepatic
steatosis and offsetting the beneficial effects of lowering blood
glucose (36). Importantly, our studies indicate that short-term
adropin34 –76 treatment promotes GK action, whereas it reduces lipogenic gene expression in DIO mice. Indeed, longterm treatment (14 days) with adropin34 –76 enhances glucose
tolerance and ameliorates insulin resistance while markedly
attenuating the development of hepatic steatosis in DIO mice
(3).
ER stress plays a causal role in the development of hepatic
insulin resistance and hepatic steatosis in obesity (37, 38). Our
data show that adropin’s actions diminish ER stress responses
in the liver of DIO mice, which can underlie both the enhancement of hepatic insulin signaling actions and the attenuation of
hepatic lipogenesis by adropin. Chronic ER stress promotes
sustained activation of JNK in obesity (7, 19), and JNK activation further antagonizes IRS’s signaling, which leads to insulin
resistance (7). Adropin34 –76 treatment suppressed hepatic JNK
J. Biol. Chem. (2019) 294(36) 13366 –13377
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Figure 9. Adropin34 –76 treatment suppresses glucose production in primary mouse hepatocyte. A, glucose production from the hepatocytes was
determined by quantifying glucose levels in culture media. The assay was performed from three hepatocyte preparations, and the data were pooled and
presented as a percentage of the vehicle-treated values (n ⫽ 10). The levels of glucose production in the vehicle-treated group were around 0.1 mg/mg of
protein/h. B, cAMP levels in HEPG2 liver cells were measured in the presence of increasing levels of forskolin (an activator of adenylate cyclase) in the culture
media. The experiments were repeated three times. C, the phosphorylation levels of Ser133 in CREB and total CREB levels, and the phosphorylation levels of PKA
substrates in the hepatocytes were determined by Western blotting (n ⫽ 2). Heat shock protein 90 (Hsp90) was used as the loading control. D, the message
levels of glucose production genes, including G6Pase (G6pc) (n ⫽ 5) and PEPCK (Pck1) (n ⫽ 2–3), in the hepatocytes were determined by real-time PCR. The
quantitation of Pck1 was repeated in another experiment (n ⫽ 3), and the levels of Pck1 in the adropin-treated group were below the detection limit.
Hypoxanthine guanine phosphoribosyltransferase was used as the reference gene. *, p ⱕ 0.05, adropin versus vehicle. Error bars, S.E.
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level of CRTC2 (co-activator of CREB) that translocates into
the nucleus upon PKA activation (32) was reduced following
adropin treatment. The activation of the insulin signaling pathway can dissociate CRTC from CREB, excluding CRTC from
the nucleus (32). Thus, adropin can reduce the nuclear level of
CRTC by both preventing it from entering the nucleus as a
result of the suppressed PKA activity and promoting nuclear
exclusion (of CRTC) as a consequence of the enhanced insulin
signaling action. Adropin’s effects on CREB and CRTC strongly
suggest that CREB transcriptional activity is reduced, which
then makes an additional contribution to the decreased expression of G6pc and Pck1.
cAMP-PKA signaling pathway plays a central role in mediating the effect of glucagon on hepatic glucose metabolism (13,
44). Glucagon enhances hepatic glucose production by activating the cAMP/PKA signaling pathway, which leads to up-regulation of CREB-dependent gene expression, including G6pc and
Pck1 (13, 44). Of relevance, diabetes is frequently associated
with hyperglucagonemia, and augmented hepatic glucagon
signaling actions, including activation of CREB, have been
observed in diabetic DIO mice (45). The current studies indicate that in addition to sensitizing insulin intracellular signaling, adropin may antagonize the glucagon signaling pathway in
reducing hyperglycemia. In this regard, adropin34 –76 appears to
share aspects of the molecular mechanisms underlying metformin’s actions on reducing hepatic glucose production. A
recent report shows that metformin treatment inhibits adenylate cyclase, resulting in reduction of cAMP level and phosphorylation of PKA substrates including IP3R, which leads to suppression of hepatic glucagon signaling (46).
Our in vitro data demonstrate that adropin suppresses glucose production in primary hepatocytes, which shows a direct
effect of adropin on hepatic glucose metabolism. The underlying mechanisms appear to involve adropin’s suppression of the
phosphorylations of CREB (Ser133) and other PKA substrates.
The observed direct effect on hepatocytes suggests that liver
cells express a receptor that mediates adropin’s action on
glucose metabolism in an autocrine/paracrine manner. Furthermore, recent studies have shown that adropin likely acts
through GPCRs (14, 15). The observed effect of adropin on
cAMP-PKA, a major signaling pathway downstream from
GPCR (47), is indeed in line with these reports. As the activation of inhibitory G protein (Gi) induces the decrease in
cAMP level (by suppressing adenylate cyclase) (48), the
potential adropin receptor might be coupled to Gi protein.
Thus, adropin might activate Gi protein, leading to the
decrease in cAMP level and the attenuation of PKA-mediated signaling actions. Interestingly, deficiency of the Gi subunit has been shown to impair insulin actions in liver, leading to insulin resistance (48).
Low circulating adropin level may be causally linked to the
impaired glycemic control in obesity. The circulating adropin
levels are low in diabetic DIO mice (3) as well as in obese subjects (4). Recent evidence also shows that nonhuman primates
with low plasma adropin level display enhanced sensitivity to
high-sugar diet–induced obesity and hyperglycemia (5). In light
of these findings, the current report, together with previous
studies (3, 6), has provided strong support for the potential of
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activity in DIO mice, which could be in part accounted for by
the alleviated ER stress. Our data are consistent with numerous
studies showing that the suppression of JNK activity enhances
insulin sensitivity in obesity (23). Among a variety of the distinct mechanisms underlying JNK’s effect on insulin signaling
pathway (23), our data favor the classical model (12) in which
JNK activation phosphorylates the Ser residue in IRS blocking
Tyr phosphorylation in this protein that is essential in the activation of the downstream signaling cascade. It is noteworthy
that the hepatic expression levels of pro-inflammatory cytokines were not altered along with the changes in JNK, and this is
likely due to the potential cell type–specific effect of adropin
treatment on hepatocytes. Recent evidence demonstrates that
the mice with hepatocyte-specific JNK deficiency display no
defect in the development of hepatic inflammation, and these
mice display a similar level of LPS-induced up-regulation of Tnf
as the WT control mice (39), indicating that JNK may not be a
major mediator in the expression of the pro-inflammatory
cytokines in hepatocytes.
In addition to the effect on insulin signaling, ER stress is
implicated in regulating SREBP1c activity and lipogenic gene
expression impacting hepatic steatosis (11, 37, 38). ER stress
activates SREBP1c by promoting the dissociation of BiP from
precursor SREBP1c in the ER membrane, resulting in increased
expression of lipogenic enzymes (26). Our data show that
adropin34 –76 treatment promotes the sequestration of precursor SREBP1c in the ER, thus preventing nuclear localization of
the mature form and abrogating the activation of its target lipogenic gene transcription. In addition, SREBP1c represses Irs2
transcription, thereby inhibiting hepatic insulin signaling (40).
Thus, the inactivation of SREBP1c by adropin could make an
additional contribution to the enhanced insulin-signaling pathway through up-regulating IRS2. It deserves mention that our
studies did not support a role of lipid metabolites in modulating
insulin sensitivity, as no changes in the levels of a variety of fatty
acid intermediates were detected despite the enhanced actions
of insulin-signaling mediators following adropin treatment.
Calcium plays a critical role in the ER protein folding process,
and the depletion of ER calcium level underlies the development of ER stress in obesity (28, 29). Furthermore, the calcium
channel activity of IP3R in the liver is enhanced, and the cytosolic calcium concentration increases in both genetically and
diet-induced obese mouse models (30, 41). Our studies suggest
that adropin treatment inhibits the channel activity of IP3R by
the concerted actions of PKA and AKT, which would attenuate
ER calcium efflux, thus alleviating ER stress. In support of this
prediction, it has been demonstrated that blocking the channel activity of IP3R, resulting in suppression of ER calcium
release, attenuates ER stress (42). Alternatively, the alleviation of ER stress by adropin may be caused by the potential
reduction of ER membrane lipid saturation (43), as we
observed a trend of decrease in the degree of saturation of
major cellular fatty acyl-CoAs. However, the analysis of lipid
saturation degree specifically in ER membrane is warranted
to assess this hypothesis.
As with the IP3R, the reduced phosphorylation of CREB
(Ser133) following adropin treatment likely results from the
effects on cAMP level and PKA activity. In parallel, the nuclear
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experimental stress. Injections of adropin34 –76 were administered after the animals had become fully habituated. The mice
subject to the experimental procedures were around 24 weeks
old. The animals were maintained under ad libitum fed conditions throughout the injection process.
Treatment with adropin34 –76

Blood glucose and insulin determination

Figure 10. A model of adropin actions in regulating hepatic glucose
metabolism. AC, adenylate cyclase.

Blood glucose levels were determined by a OneTouch blood
glucose meter (LifeScan Europe, Zug, Switzerland). Insulin levels (serum and plasma) were determined by ELISA (Crystal
Chem, Downers Grove, IL).
Glycogen and triacylglycerol assays

adropin therapy in improving glycemic control in obesity.
Regarding the prospect of therapeutic potential, it also deserves
mention that the high-dose adropin treatment appears to exert
a liver-protective role. A recent report demonstrates that acute
treatment of adropin with a similar dose (500 nmol/kg intraperitoneally) significantly reduces serum levels of alanine aminotransferase and aspartate aminotransferase in a mouse
model of nonalcoholic steatohepatitis (49).
In conclusion, our data show that adropin34 –76 treatment modulates major intracellular signaling pathways in the liver to reduce
hyperglycemia in diet-induced obesity (Fig. 10). These signaling
actions appear to underlie peptide adropin’s therapeutic potential
of suppressing fasting hyperglycemia and improving glycemic
control in obesity-associated type-2 diabetes.

Experimental procedures
Animals
Mouse experiments were approved by the Institutional Animal Care and Use Committees of the Scripps Research Institute
(Jupiter, FL) and the University of Alberta Health Sciences Animal Welfare Committee.
Male DIO B6 mice that were weaned on an HFD (60% kcal
fat; New Brunswick, NJ) were purchased from the Jackson Laboratory (Bar Harbor, ME) and were housed in a light/dark (12h/12-h) cycle-controlled room at a temperature of 26 °C. The
mice were maintained on the same HFD until they were used. In
a separate experiment, age-matched C57BL/6 WT mice maintained on a laboratory chow diet (low-fat diet) and DIO B6 mice
maintained on an HFD were used as the control.
Mice were monitored and handled daily for habituation and
were subject to repeated mock injections to minimize the

The levels of glycogen and triacylglycerol in the liver were
measured by the Glycogen Assay Kit from Abcam (Cambridge,
MA) and the Triglyceride Colorimetric Assay Kit from Cayman
(Ann Arbor, MI) according to the manufacturers’ instructions,
which were described previously (6).
Measurement of lipid metabolites
Lipid metabolites were analyzed with HPLC as described
before (6) and by Metabolon (Durham, NC).
Western blotting
Whole-cell lysate of liver was prepared by use of the protocol
from Cell Signaling Technology. Nuclear extract was prepared
with the Nuclear Extraction Kit from Active Motif (Carlsbad,
CA). Microsomal membranes were isolated as described previously (26).
Immunoprecipitation and immunoblotting procedures,
based on the protocols detailed by Cell Signaling Technology
and Invitrogen (Carlsbad, CA), were described in the previous
studies (2, 6). Co-immunoprecipitation was performed as
described previously (26). In general, the protein extracts were
heated at 70 ºC for 10 min before gel loading.
The antibodies against phospho-IRS1 (Ser307), phosphoIRS1 (Tyr608), and histone H3 were from EMD Millipore
(Mahopac, NY). The antibodies against XBP-1, SREBP1c,
NF-B-p65, and ␤-actin were from Santa Cruz Biotechnology,
Inc. (Dallas, TX). The antibody against BiP was from Abcam.
The antibody against CRTC2 was from Bethyl Laboratories
(Montgomery, TX). All of the other primary antibodies were
from Cell Signaling Technology (Danvers, MA). GAPDH, ␤-actin, and ␣-tubulin were used as the loading control in wholeJ. Biol. Chem. (2019) 294(36) 13366 –13377
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Adropin34 –76 purchased from ChinaPeptides (Shanghai,
China) (2, 3, 6) was dissolved in 0.1% BSA/PBS solution, and
administered as five intraperitoneal injections (450 nmol/kg for
each injection) over a 48-h period to DIO mice fed ad libitum
(6). Body weight was measured right before the first injection
and right after the last injection, and the data were published in
the previous studies (6). Food was removed after the last injection, which took place 4 h before the dark onset, and the mice
were euthanized 2 h after the last injection. The livers were
freeze-clamped and flash-frozen in liquid nitrogen for subsequent analysis.
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liver cell lysate analysis. Histone H3 was used as the loading
control in liver nuclear extract analysis.
Proteins were visualized using enhanced chemiluminescence
(Waltham, MA), and the signals were exposed on film. In general, the same membrane was used for detecting different proteins. Whenever possible, the membranes were stripped with
OneMinute Stripping Buffer (GM Bioscience, Fredrick, MD)
and reprobed with primary antibodies for other proteins of
interest. Loading controls from the same membranes were
shared. Four to six contiguous gel bands with two to three from
each group are presented. Densitometry was performed by use
of Image J software (National Institutes of Health).

4.

5.

6.

Quantitative PCR

Primary hepatocytes
Primary hepatocytes were isolated from the WT B6 mouse as
described previously (33). 12–16 h after isolation, the hepatocytes were washed twice with PBS and starved in Hanks’ balanced salt solution for 2 h. Hepatocytes were then treated with
Hanks’ balanced salt solution containing 100 ng/ml glucagon
and 5 mM pyruvate to induce glucose production (33) with or
without 100 nM adropin (or vehicle) for 3 h. Glucose levels in
the culture media were measured with a glucose assay kit from
Sigma and were normalized to cellular protein levels.
Statistical analysis
Data values are expressed as mean ⫾ S.E. Comparisons
between the means were performed by unpaired Student’s t
test. A value of p ⱕ 0.05 is defined as statistically significant.
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